

118TH CONGRESS
1ST SESSION

H. RES. 347

Expressing support for designation of the month of April 2023 as
“Parkinson’s Awareness Month”.

IN THE HOUSE OF REPRESENTATIVES

APRIL 28, 2023

Ms. WEXTON (for herself and Mrs. KIGGANS of Virginia) submitted the following resolution; which was referred to the Committee on Energy and Commerce

RESOLUTION

Expressing support for designation of the month of April
2023 as “Parkinson’s Awareness Month”.

Whereas Parkinson’s disease—

- (1) affects over 1,000,000 individuals in the United States;
- (2) is the fastest-growing and second most common neurodegenerative disease in the world;
- (3) is believed to be caused by a combination of genetic and environmental factors, but the exact cause in most individuals is still unknown; and
- (4) is the 14th leading cause of death in the United States, according to the Centers for Disease Control and Prevention;

Whereas it is estimated that, by the year 2037, the number of individuals with Parkinson’s disease in the United States will nearly double, and the disease will cost the United States at least \$80,000,000,000 annually;

Whereas the symptoms of Parkinson’s disease can include dementia and cognitive impairment, tremors, slowness of movement and rigidity, gait and balance difficulties, speech and swallowing difficulties, depression, and a variety of other symptoms;

Whereas there are millions of family caregivers, friends, and loved ones whose lives are greatly affected by Parkinson’s disease; and

Whereas more research, education, and community support services are needed to—

(1) find better treatments and a cure for Parkinson’s disease; and

(2) maintain dignity for those living with the disease today: Now, therefore, be it

1 *Resolved*, That the House of Representatives—

2 (1) supports the designation of “Parkinson’s
3 Awareness Month”;

4 (2) supports the goals and ideals of Parkinson’s
5 Awareness Month;

6 (3) continues to support research to find better
7 treatments and a cure for Parkinson’s disease;

8 (4) recognizes the individuals living with Par-
9 kinson’s disease who participate in vital clinical
10 trials to advance the knowledge of the disease; and

1 (5) commends the dedication of organizations,
2 volunteers, researchers, and millions of individuals
3 across the country working to improve the quality of
4 life of people living with Parkinson's disease and
5 their families.

○